Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $50.0M | $271M | $386M | $638M |
| Revenue growth | — | — | — | — | — | — | — | 440.8% | 42.5% | 65.5% |
| Operating income | -$27.5M | -$27.2M | -$32.8M | -$67.2M | -$99.1M | -$125M | -$180M | -$232M | -$281M | -$167M |
| Operating margin | — | — | — | — | — | — | -359.3% | -85.7% | -72.7% | -26.1% |
| Net income | -$27.2M | -$28.9M | -$31.0M | -$68.3M | -$103M | -$130M | -$187M | -$239M | -$287M | -$183M |
| Net margin | — | — | — | — | — | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (diluted) | -$1.42 | -$1.27 | -$1.15 | -$2.01 | -$2.77 | -$3.47 | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.3M | -$26.5M | -$30.1M | -$46.4M | -$78.5M | -$108M | -$117M | -$145M | -$128M | -$93.4M |
| Capital expenditures | $105K | $9.90K | $32.7K | $16.1K | $45.9K | $308K | $702K | $582K | $270K | $480K |
| Free cash flow | -$21.4M | -$26.5M | -$30.1M | -$46.4M | -$78.5M | -$109M | -$117M | -$146M | -$129M | -$93.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $220M | $184M | $86.5M | $201M | $386M | $315M | $323M |
| Total assets | $38.2M | $35.6M | $15.4M | $221M | $186M | $87.8M | $331M | $588M | $568M | $690M |
| Total liabilities | $16.6M | $18.8M | $14.4M | $41.8M | $72.3M | $72.2M | $222M | $397M | $511M | $602M |
| Long-term debt | $9.47M | $6.66M | $3.62M | $17.3M | $48.3M | $49.1M | $94.3M | $178M | $181M | $118M |
| Shareholders' equity | $21.6M | $16.7M | $938K | $179M | $114M | $15.6M | $110M | $191M | $57.0M | $88.3M |
| Retained earnings | -$47.6M | -$76.6M | -$108M | -$176M | -$279M | -$409M | -$596M | -$836M | -$1.12B | -$1.31B |
| Shares (wtd avg diluted) | 19.1M | 25.5M | 30.1M | 36.9M | 37.2M | 37.6M | 40.7M | 45.4M | 47.9M | 49.7M |
Every figure is extracted from Axsome Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.